nejm tirzepatide New in the January 30, 2025, issue of NEJM: for Heart Failure and Obesity (SUMMIT trial) https://nej.md/4hRGaTY Continuation of Oral Anticoagulation during TAVI (POPular PAUSE TAVI trial) https://nej.md/3XllHys Lentiviral Gene Therapy 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

Similarly, impaired kidney function can slow clearance, potentially increasing exposure and side effect risk for the same nominal dose

Who Is at Higher Risk for Problematic Heart Rate Changes Patients with existing arrhythmias such as atrial fibrillation, those with symptomatic tachycardia, uncontrolled coronary disease, or advanced heart failure need closer attention

Like SABAs, LABAs, due to beta-receptor agonism, can cause increased heart rate, chest pain, chest palpitations, body tremors, and nervousness (7)

Research supports that L-Lysine improves calcium absorption as well as reducing calcium excretion helping with bone strength